

Kinexum Congratulates TIXiMED

Kinexum congratulates TIXiMED on obtaining clearance from the US FDA to commence clinical testing of its TIX100.

WASHINGTON, DC, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Kinexum congratulates TIXiMED (www.tiximed.com) on obtaining clearance from the US FDA to commence clinical testing of its TIX100, an innovative small molecule targeting TXNIP, for Type 1 and Type 2 Diabetes. This is a major milestone in the development of the company's novel approach to the treatment of Type 1 and Type 2 diabetes and gives TIXiMED the go ahead to start its human clinical trials with TIX100.

[TIXiMED Receives IND Approval from the FDA](#) for its Novel Oral Antidiabetic, TIX100.



Kinexum acted as regulatory advisor to TIXiMED in connection with its IND application.

For more information on Kinexum's services, please visit www.kinexum.com.

Michael Zemel
Kinexum Services
michaelzemel@kinexum.com

This press release can be viewed online at: <https://www.einpresswire.com/article/729591382>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.